An anti-diabetic drug targets NEET (CISD) proteins through destabilization of their [2Fe-2S] clusters

Marjault et al. report two crystal structures of a drug molecule bound to NEET proteins mNT and NAF-1 and the effects of this molecule on diabetic mice, suggesting an approach for reducing mitochondrial iron and ROS levels in diabetic patients. Elevated levels of mitochondrial iron and reactive oxygen species (ROS) accompany the progression of diabetes, negatively impacting insulin production and secretion from pancreatic cells. In search for a tool to reduce mitochondrial iron and ROS levels, we arrived at a molecule that destabilizes the [2Fe-2S] clusters of NEET proteins (M1). Treatment of db/db diabetic mice with M1 improved hyperglycemia, without the weight gain observed with alternative treatments such as rosiglitazone. The molecular interactions of M1 with the NEET proteins mNT and NAF-1 were determined by X-crystallography. The possibility of controlling diabetes by molecules that destabilize the [2Fe-2S] clusters of NEET proteins, thereby reducing iron-mediated oxidative stress, opens a new route for managing metabolic aberration such as in diabetes.

Automated summary

Marjault et al. report the crystal structures of a drug molecule bound to NEET proteins and its effects on diabetic mice. They found that this molecule can reduce hyperglycemia in diabetic mice without causing weight gain. This study suggests a new approach for managing diabetes by targeting NEET proteins.